123 results
Page 2 of 7
8-K
EX-99.1
4w66g zqxrap4gq14s
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
EX-99.1
zlo5oodgo0nqbp
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
424B5
5iq2k6ixf n82fn7twq
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
i3ip8k3
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
gjg0g e0x
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
4oyjdtkz hvum31e16d
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
xqksv w6csqwu2noulc
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
424B3
emndze
19 Jan 22
Prospectus supplement
4:05pm
8-K
84gq1gnk0lqtlgkqbr
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
7yht01sn21i4p8
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
fx5d8pgm 87
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
j13pf
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
c2yha anv1tnt
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
p3f1g20 hva
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
t0yzshg2dgyg4
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am